FDA lets 2 cancer drugs be imported
Dire shortages of two critical cancer drugs—shortfalls that have threatened the lives and care of thousands of patients—should be resolved within weeks, federal drug officials said. In the case of Doxil, the F.D.A. has decided to allow temporary shipments from India of Lipodox, which is similar to Doxil and is made by Sun Pharma Global. And the pharmaceutical company Hospira is rushing 31,000 vials—enough to last the entire nation a month—of preservative-free methotrexate from its plant in Australia to the United States. Hospitals began receiving the drug, which is vital in the treatment of a common form of childhood leukemia, on Tuesday.
- mHealth Tackles Readmissions
- 'Kafkaesque' Value System Unfairly Penalizes Doctor Pay
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Targeting Self-Insured Populations
- MA an Insurance Proving Ground for Providers
- Proton Beam Therapy Poised for Growth in US
- Sharp HealthCare Leaves Pioneer ACO Program
- Some Cancer Hospitals' Quality Data Will Soon Be Public
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- Docs Fret as HHS Addresses Malpractice Reporting 'Loopholes'